AFYREN SAAFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill long-term contracts across key sectors like nutrition, cosmetics, and life sciences. European Biotech News talked to CEO Nicolas Sordet about the long and winding road to sucess.
Tag Archive for: impact
Ovid Therapeutics - Jeremy LevinBy Jeremy Levin, D.Phil, MB BChir
Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in 2015 according to the company´s statement.